<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1211246207
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LIPIZET 10MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EZETIMIBE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        110.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LABORATORIOS CINFA SA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AX09 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lipizet is a medicine to lower increased levels of cholesterol.</p><p>Lipizet lowers levels of total cholesterol, &ldquo;bad&rdquo; cholesterol (LDL cholesterol), and fatty substances called triglycerides in the blood. In addition, Lipizet raises levels of &ldquo;good&rdquo; cholesterol (HDL cholesterol).</p><p>Ezetimibe, the active ingredient of Lipizet, works by reducing the cholesterol absorbed in your digestive tract.</p><p>Lipizet adds to the cholesterol-lowering effect of statins, a group of medicines that reduce the cholesterol your body makes by itself.</p><p>Cholesterol is one of several fatty substances found in the bloodstream. Your total cholesterol is made up mainly of LDL and HDL cholesterol.</p><p>LDL cholesterol is often called &ldquo;bad&rdquo; cholesterol because it can build up in the walls of your arteries forming plaque. Eventually this plaque build-up can lead to a narrowing of the arteries. This narrowing can slow or block blood flow to vital organs such as the heart and brain. This blocking of blood flow can result in a heart attack or stroke.</p><p>HDL cholesterol is often called &ldquo;good&rdquo; cholesterol because it helps keep the bad cholesterol from building up in the arteries and protects against heart disease.</p><p>Triglycerides are another form of fat in your blood that may increase your risk for heart disease.</p><p>It is used for patients who cannot control their cholesterol levels by cholesterol lowering diet alone. You should stay on your cholesterol lowering diet while taking this medicine.</p><p><em><u>Lipizet</u></em><em><u> </u></em><em><u>is used in addition to your cholesterol lowering diet if you have:</u></em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a raised cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial])</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; together with a statin, when your cholesterol level is not well controlled with a statin alone</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alone, when statin treatment is inappropriate or is not tolerated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a hereditary illness (homozygous familial hypercholesterolaemia) that increases the cholesterol level in your blood. You will also be prescribed a statin and may also receive other treatments.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a hereditary illness (homozygous sitosterolaemia, also known as phytosterolaemia) that increases the levels of plant sterols in your blood.</p><p>If you have heart disease, Lipizet combined with cholesterol-lowering medicines called statins reduces the risk of heart attack, stroke, surgery to increase heart blood flow, or hospitalisation for chest pain.</p><p>Lipizet does not help you lose weight.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>If you use Lipizet together with a statin, please read the package leaflet of that particular medicine.</p><p>&nbsp;</p><p>Do not take Lipizet if:</p><p><strong>&nbsp;</strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic (hypersensitive) to ezetimibe or any of the other ingredients of this medicine (see Section 6: Contents of the pack and other information).</p><p>Do not take Lipizet together with a statin if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you currently have liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are pregnant or breast-feeding.</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Lipizet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor about all your medical conditions including allergies.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor should do a blood test before you start taking Lipizet with a statin. This is to check how well your liver is working.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may also want you to have blood tests to check how well your liver is working after you start taking Lipizet with a statin.</p><p>If you have moderate or severe liver problems, Lipizet is not recommended.</p><p>The safety and efficacy of the combined use of Lipizet and certain cholesterol lowering medicines, the fibrates have not been established.</p><p>Children and adolescents</p><p>Do not give this medicine to children and adolescents (6 to 17 years of age) unless prescribed by a specialist because there are limited data on safety and efficacy.</p><p>Do not give this medicine to children less than 6 years old because there is no information in this age group.</p><p>Other medicines and Lipizet</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular, tell your doctor if you are taking medicine(s) with any of the following active ingredients:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin (often used in organ transplant patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines with an active ingredient to prevent blood clots, such as warfarin, phenprocoumon, acenocoumarol or fluindione (anticoagulants)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; colestyramine &nbsp;(also &nbsp;used &nbsp;to &nbsp;lower &nbsp;cholesterol), &nbsp;because &nbsp;it &nbsp;affects &nbsp;the &nbsp;way Lipizet works</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fibrates (also used to lower cholesterol)</p><p>Pregnancy and breast-feeding</p><p>Do not take Lipizet with a statin if you are pregnant, are trying to get pregnant or think you may be pregnant. If you get pregnant while taking Lipizet with a statin, stop taking both medicines immediately and tell your doctor.</p><p>There is no experience from the use of Lipizet without a statin during pregnancy. Ask your doctor for advice before using Lipizet if you are pregnant.</p><p>Do not take Lipizet with a statin if you are breast-feeding, because it is not known if the medicines are passed into breast milk.</p><p>Lipizet without a statin should not be used if you are breast-feeding. &nbsp;Ask your doctor for advice.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Driving and using machines</p><p>Lipizet is not expected to interfere with your ability to drive or to use machinery. However, it should be taken into account that some people may get dizzy after taking Lipizet.</p><p>Lipizet contains lactose.</p><p>Lipizet tablets contain a sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.<br /><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Continue taking your other cholesterol-lowering medicines unless your doctor tells you to stop. You should check with your doctor or pharmacist if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before starting Lipizet, you should be on a diet to lower your cholesterol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should keep on this cholesterol lowering diet whilst taking Lipizet. The recommended dose is one Lipizet 10 mg Tablet by mouth once a day. Take Lipizet at any time of the day. You can take it with or without food.</p><p>If your doctor has prescribed Lipizet along with a statin, both medicines can be taken at the same time. In this case, please read the dosage instructions in the package leaflet of that particular medicine.</p><p>If your doctor has prescribed Lipizet along with another medicine for lowering cholesterol containing the active ingredient colestyramine or any other medicine containing &nbsp;bile acid sequestrant, you should take Lipizet at least 2 hours before or 4 hours after taking the bile acid sequestrant.</p><p>If you take more Lipizet than you should</p><p>Please contact your doctor or pharmacist.</p><p>If you forget to take Lipizet</p><p>Do not take a double dose to make up for a forgotten tablet, just take your normal amount of Lipizet at the usual time the next day.</p><p>If uou stop taking Lipizet</p><p>Talk to your doctor or pharmacist because your cholesterol may rise again.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following terms are used to describe how often side effects have been reported:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common (may affect more than 1 of 10 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common (may affect up to 1 of 10 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon (may affect up to 1 of 100 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare (may affect up to 1 of 1,000 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare (may affect up to 1 of 10,000 patients, including isolated reports).</p><p>&nbsp;</p><p>Contact your doctor immediately if you experience unexplained muscle pain, tenderness, or weakness. This is because on rare occasions, muscle problems, including muscle breakdown resulting in kidney damage, can be serious and may become a potentially life-threatening condition.</p><p>Allergic reactions, including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing (which requires treatment right away) have been reported in general use.</p><p>When used alone, the following side effects were reported: Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain; diarrhoea; flatulence; feeling tired.</p><p>Uncommon: elevations in some laboratory blood tests of liver (transaminases) or muscle (CK) function; cough; indigestion; heartburn; nausea; joint pain; muscle spasms; neck pain; decreased appetite, pain, chest pain, hot flush; high blood pressure.</p><p>Additionally, when used with a statin, the following side effects were reported:</p><p>Common: elevations in some laboratory blood tests of liver function (transaminases); headache; muscle pain, tenderness or weakness.</p><p>Uncommon: tingling sensation; dry mouth; itching; rash; hives; back pain; muscle weakness; pain in arms and legs; unusual tiredness or weakness; swelling, especially in the hands and feet.</p><p>When used with fenofibrate, the following common side effect was reported: abdominal pain.</p><p>Additionally, the following side effects have been reported in general use: dizziness; muscle aches; liver problems; allergic reactions including rash and hives; raised red rash, sometimes with target-shaped lesions (erythema multiforme); muscle pain, tenderness or weakness; muscle breakdown; gallstones or inflammation of the gallbladder (which may cause abdominal pain, nausea, vomiting); inflammation of the pancreas often with severe abdominal pain; constipation, reduction in blood &nbsp;cell counts, which may cause bruising/bleeding (thrombocytopaenia); tingling sensation; depression: unusual tiredness or weakness; shortness of breath.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton or container after &quot;EXP.&quot; The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store Lipizet above 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is ezetimibe. Each tablet contains 10 mg ezetimibe.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: lactose monohydrate, microcrystalline cellulose, povidone, sodium croscarmellose , sodium laurilsulfate, sodium stearyl fumarate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lipizet tablets are white, oblong, flat beveled, non-scored tablets engraved with the code
"EZ1". Each pack contains 28 tablets (7’s blister x 4).	


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Laboratorios Cinfa, S.A.</p><p>Olaz-Chipi, 10 &ndash; Pol&iacute;gono Industrial Areta</p><p>31620 Huarte &ndash; Pamplona (Navarra) &ndash; Spain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in August 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ليبيزيت هو دواء يخفض المستويات المرتفعة من الكوليستيرول.</p><p dir="RTL">يخفض ليبيزيت مستويات الكوليستيرول الكلي، الكوليستيرول &quot;الضار&quot; (كوليستيرول البروتينات الشحمية المنخفضة الكثافة)، والمواد الدهنية التي تسمى الجليسريدات الثلاثية &nbsp;في الدم. بالإضافة إلى ذلك، يزيد ليبيزيت مستويات الكوليستيرول &quot;النافع&quot; (كوليستيرول البروتينات الشحمية المرتفعة الكثافة).</p><p dir="RTL">يعمل الإيزيتميب، وهو المادة الفعالة لدواء ليبيزيت، عن طريق تخفيض الكوليستيرول الممتص من القناة الهضمية.</p><p dir="RTL">يُضاف ليبيزيت إلى التأثيرات الخافضة للكوليستيرول للستاتينات، وهي مجموعة من الأدوية تخفض الكوليستيرول المُصَنَّع في الجسم.</p><p dir="RTL">الكوليستيرول هو أحد المواد الدهنية العديدة الموجودة في مجرى الدم. يتكون الكوليستيرول الكلي من البروتينات الشحمية المنخفضة الكثافة والبروتينات الشحمية المرتفعة الكثافة بشكل رئيسي.</p><p dir="RTL">غالباً ما يطلق على كوليستيرول البروتينات الشحمية المنخفضة الكثافة &quot;الضار&quot; نظراً لتراكمه في جدران الشرايين مشكلاً ترسبات. وفي النهاية قد يؤدي تراكم هذه الترسبات إلى ضيق الشرايين. قد يُبطئ هذا الضيق أو يعيق جريان الدم إلى الأعضاء الحيوية مثل القلب والدماغ. إعاقة لجريان الدم قد تتسبب في حدوث الجلطة (النوبة) القلبية أو السكتة الدماغية.</p><p dir="RTL">غالباً ما يطلق على كوليستيرول البروتينات الشحمية المرتفعة الكثافة &quot;النافع&quot; لمنعه تراكم الكوليستيرول الضار في الشرايين ومنع حدوث الأمراض القلبية.</p><p dir="RTL">&nbsp;الجليسريدات الثلاثية هي شكل آخر من الشحم (الدهن) توجد في الدم وقد تزيد من خطر حدوث الأمراض القلبية.</p><p dir="RTL">يُستخدم في المرضى الذين لا يستطيعون ضبط مستويات الكوليستيرول عن طريق خضوعهم للنظام الغذائي الخاص بتخفيض الكوليستيرول وحده. ينبغي الاستمرار على النظام الغذائي الخاص بتخفيض الكوليستيرول أثناء تناول هذا الدواء.</p><p dir="RTL"><em><u>يُستعمل ليبيزيت بالإضافة إلى النظام الغذائي الخاص بتخفيض الكوليستيرول إذا كنت تعاني من: </u></em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الكوليستيرول في الدم (فرط كوليستيرول الدم &quot;الأولي&quot; بما فى ذلك فرط كوليستيرول الدم &quot;العائلي والغير عائلى النوع متابين الجينات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالاشتراك مع أحد الأستاتين، في حال عدم ضبط مستوى الكوليستيرول بشكل جيد عند استعمال أحد الأستاتين وحده.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستعمل وحده، في حال عدم العلاج غير الملائم بأحد الأستاتين أو عدم تحمله.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض وراثي مثل (فرط كوليستيرول الدم العائلي النوع متابين الجينات) والذي يسبب زيادة مستوى الكوليستيرول في الدم. قد يُوصف العلاج بأحد الأستاتين أيضاً وقد يجري إعطاؤك علاجات أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض وراثي مثل (سيتوستيروليميا متماثل الجينات، المعروف أيضاً باسم فيتوستيروليميا) الذي يزيد من مستويات ستيرول النبات في الدم.</p><p dir="RTL">إذا كنت تعاني من أمراض القلب، فإن تناول ليبيزيت مع أدوية خفض الكوليستيرول التى تسمى الأستاتين يقلل من خطر الإصابة بأزمة قلبية، السكتة الدماغية، الجراحة لزيادة تدفق الدم في القلب، أو ألم في الصدر يستلزم العلاج في المستشفى.</p><p dir="RTL">لا يساعد ليبيزيت على فقدان الوزن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إذا كنت تستعمل ليبيزيت بالاشتراك مع أحد الأستاتين، يرجى قراءة النشرة الدوائية لذلك الدواء المستعمل.</p><p dir="RTL"><strong>لا تتناول ليبيزيت إذا: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من حساسية (فرط التحسس) للإيزيتميب أو أي من مكونات الدواء الأخرى (انظر القسم 6: محتويات العلبة ومعلومات أخرى).</p><p dir="RTL"><strong>لا تتناول ليبيزيت بالتزامن مع أحد الأستاتين إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشاكل حالية في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ حاملاً أو مرضعة.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل البدء في تناول ليبيزيت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك عن حالتك المرضية الطبية بما فيها الحساسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على الطبيب القيام بإجراء اختبار للدم قبل البدء في تناول ليبيزيت بالاشتراك مع أحد الأستاتين، يُجرَى هذا الاختبار لفحص حالة عمل الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يطلب طبيبك إجراء اختبارات للدم لفحص حالة عمل الكبد بعد البدء في تناول ليبيزيت بالاشتراك مع أحد الأستاتين.</p><p dir="RTL">إذا كنت تعانى من مشاكل متوسطة أو شديدة فى الكبد، لا يوصى باستعمال ليبيزيت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم يتم إثبات أو التأكد من أمان وفاعلية الاستعمال المشترك لليبيزيت وبعض الأدوية المخفضة للكوليستيرول مثل الفيبرات.</p><p dir="RTL"><strong>الأطفال والمراهقون </strong></p><p dir="RTL">لا يجوز استخدام هذا الدواء في الأطفال والمراهقين (عمر 6 إلى17 عام) ما لم يتم وصفه عن طريق أخصائي نظراً لتوافر معلومات محدودة حول الأمان والفاعلية. لا يجوز استخدام هذا الدواء في الأطفال الذين تقل أعمارهم عن 6 أعوام نظراً لعدم وجود معلومات تخص هذه الفئة العمرية.</p><p dir="RTL"><strong>التفاعلات مع الأدوية الأخرى </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت أي أدوية مؤخراً أو احتمال تناولك لأدوية أخرى. بشكل خاص، أخبر طبيبك إذا كنت تتناول دواء/ أدوية تحتوي على أي من المواد الفعالة التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيكلوسبورين (وغالباً ما يُستخدم في مرضى زراعة الأعضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تحتوي على مادة فعالة تمنع تشكيل جلطات الدم أو مثل الورافارين أو الفينوبروكومون، الأسينوكومارول أو الفلوينديون (مضادات التخثر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكوليسترامين (يُستخدم في تخفيض مستوى الكوليستيرول أيضاً)، لأنه يؤثر في طريقة تأثير ليبيزيت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفيبرات (تُستخدم في تخفيض مستوى الكوليستيرول أيضاً)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">لا يجوز تناول ليبيزيت مع أحد الأستاتين إذا كنتِ حاملاً، أو تخططين لحدوث الحمل أو تعتقدين بوجود حمل. إذا حدث الحمل أثناء تناول ليبيزيت مع أحد الأستاتين، فامتنعي عن تناول كلا الدوائين في الحال وأخبري طبيبك.</p><p dir="RTL">لا تتوافر معلومات حول استخدام ليبيزيت وحده أثناء الحمل.</p><p dir="RTL">استشيري طبيبك قبل استخدام ليبيزيت إذا كنتِ حاملاً.</p><p dir="RTL">لا تتناولي ليبيزيت بالاشتراك مع أحد الأستاتين إذا كنتِ مرضعاً، لعدم توافر معلومات حول مرور وإفراز تلك الأدوية إلى لبن الأم.</p><p dir="RTL">يجب عدم استخدام ليبيزيت وحده بدون الأستاتين إذا كنتِ مرضعاً. ويفضل استشارة الطبيب.</p><p dir="RTL">يفضل استشارة طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر ليبيزيت في قدرتك على القيادة أو استعمال الآلات. ومع ذلك، ينبغي أن يؤخذ بعين الاعتبار إمكانية شعور بعض الأشخاص بالدوخة بعد تناول ليبيزيت.</p><p dir="RTL"><strong>يحتوي ليبيزيت على اللاكتوز</strong></p><p dir="RTL">تحتوي أقراص ليبيزيت على سكر يدعى اللاكتوز. إذا ما أخبرك طبيبك بأنك تعاني من عدم تحمل بعض السكريات، فاتصل بطبيبك قبل تناول هذا المستحضر الطبي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول ليبيزيت دائماً كما أخبرك طبيبك تماماً. استمر في تناول الأدوية المخفضة للكوليستيرول الأخرى ما لم يخبرك طبيبك بإيقاف استعمالها. ينبغي مراجعة طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي اتباع نظام غذائي خاص لتخفيض الكوليستيرول، قبل البدء في تناول ليبيزيت.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي الاستمرار على النظام الغذائي الخاص بتخفيض الكوليستيرول أثناء تناول ليبيزيت.</p><p dir="RTL">تبلغ الجرعة الموصى بها قرصاً واحداً 10 ملجم مرة واحدة يومياً عن طريق الفم. تناول ليبيزيت في أي وقت من اليوم. يمكنك تناوله مع الطعام أو بدونه.</p><p dir="RTL">إذا وصف الطبيب ليبيزيت بالاشتراك مع أحد الأستاتين، يمكن تناول الدوائين معاً في نفس الوقت. في هذه الحالة، يرجى الاطلاع على التعليمات الخاصة بالجرعة في النشرة الدوائية الخاصة بذلك الدواء.</p><p dir="RTL">إذا ما وصف الطبيب ليبيزيت بالاشتراك مع دواء آخر مُخَفِّض للكوليستيرول يحتوي على المادة الفعالة الكوليسترامين أو أي دواء آخر يحتوي على الراتينات الرابطة للحمض الصفراوي، يجب تناول ليبيزيت قبل ساعتين على الأقل أو بعد 4 ساعات من تناول أحد أدوية الراتينات الرابطة للحمض الصفراوي.</p><p dir="RTL"><strong>في حال تجاوز الجرعة الموصي بها من ليبيزيت</strong></p><p dir="RTL">يرجى الاتصال بطبيبك أو الصيدلي.</p><p dir="RTL"><strong>إذا نسيت تناول ليبيزيت</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة المَنْسِيَّة، فقط تناول الجرعة الطبيعية من ليبيزيت في الوقت المعتاد من اليوم التالي.</p><p dir="RTL"><strong>إذا توقفت عن تناول ليبيزيت</strong></p><p dir="RTL">اتصل بطبيبك أو الصيدلي لاحتمال ارتفاع مستوى الكوليستيرول مرة أخرى.</p><p>إذا كان لديك أي أسئلة أخرى عن طريقة استعمال هذا الدواء، فاسأل الطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب هذا الدواء آثاراً جانبية، ولكنها لا تظهر بالضرورة على كل من يتناوله.</p><p dir="RTL">تستعمل المصطلحات التالية في وصف نسبة حدوث الآثار الجانبية المُبَلَّغ عنها:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شائعة جداً (قد تصيب أكثر من مريض من كل 10 مرضى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شائعة (قد تصيب مريضاً واحداً من كل 10 مرضى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غير شائعة (قد تصيب مريضاً واحداً من كل 100 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرة الحدوث (قد تصيب مريضاً واحداً من كل 1000 مريض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرة الحدوث جداً (قد تصيب مريضاً واحداً من كل 10000 مريض، وتشمل الحالات المنفردة المُبَلَّغ عنها)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اتصل بطبيبك في الحال إذا ما شعرت بآلام غير مفسرة أو ضعف في العضلات. يحدث هذا لأنه في بعض الحالات النادرة الحدوث، تتسبب المتاعب العضلية، وتشمل تدهور العضلات في حدوث فشل كلوي قد يكون شديداً وقد يصبح حالة مرضية مُهَدِّدَة للحياة.</strong></p><p dir="RTL">أُبْلِغَ عن حدوث ردات فعل تحسسية في الاستخدام العام ، وتشمل انتفاخ الوجه، الشفاه، اللسان، و/أو الحنجرة والتي قد تتسبب في حدوث صعوبة في التنفس أو البلع (والتي تتطلب علاجاً في الحال).</p><p dir="RTL">عند استعماله بمفرده، جرى الإبلاغ عن حدوث الآثار الجانبية التالية:</p><p dir="RTL">شائعة: آلام في البطن؛ الإسهال؛ انتفاخ البطن؛ الشعور بالتعب.</p><p dir="RTL">غير شائعة: ارتفاع في بعض نتائج اختبارات الدم المعملية الخاصة بالكبد أو وظائف العضلات؛ السعال، عسر الهضم، حرقة المعدة؛ الغثيان؛ آلام في المفاصل؛ التشنج العضلي؛ آلام فى الرقبة؛ فقدان الشهية، آلام، آلام في الصدر، هبات ساخنة؛ ارتفاع ضغط الدم.</p><p dir="RTL">بالإضافة إلى ذلك، وعندما يُستعمل مع أحد الأستاتين، تم الإبلاغ عن حدوث الآثار الجانبية التالية:</p><p dir="RTL">شائعة: ارتفاع في بعض نتائج اختبارات الدم المعملية الخاصة بالكبد؛ الصداع؛ آلام أو ضعف في العضلات.</p><p dir="RTL">غير شائعة: الإحساس بالنخز؛ جفاف الفم؛ الحكة؛ الطفح الجلدي؛ الشرى (الأرتيكاريا)، آلام الظهر؛ ضعف العضلات، آلام في الذراعين والساقين؛ الإرهاق أو الضعف غير المعتاد؛ التورم، خصوصاً في اليدين والقدمين.</p><p dir="RTL">عندما يستعمل بالاشتراك مع الفينوفيبرات، تم الإبلاغ عن حدوث الآثار الجانبية الشائعة التالية: آلام في البطن.</p><p dir="RTL">&nbsp;بالإضافة إلى ذلك، تم الإبلاغ عن حدوث الآثار الجانبية التالية في الاستخدام العام: الدوخة؛ وجع العضلات، مشاكل كبدية، ردة الفعل التحسسية وتشمل الطفح الجلدي، الشرى (الأرتيكاريا)؛ طفح جلدي أحمر بارز؛ آفات محددة الشكل (حمامي عديدة الأشكال)؛ آلام أو ضعف في العضلات ؛ تدهور العضلات، حصوات فى المرارة أو التهاب المرارة (والتي قد تتسبب في حدوث آلام في البطن، غثيان، قيء)؛ التهاب البنكرياس ويكون مصحوباً بآلام شديدة في البطن في أغلب الأحيان؛ الإمساك، انخفاض في عدد خلايا الدم، والتي قد تتسبب في حدوث كدمات/النزيف (الصفائح الدموية)؛ الإحساس بالوخز؛ الاكتئاب، الإرهاق أو الضعف غير المعتاد؛ ضيق فى التنفس.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت عليك أي آثار جانبية، فاستشر طبيبك أو الصيدلي. ويشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). يمكنك المساعدة في تقديم معلومات أكثر حول مدى أمان هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العلبة الخارجية أو الشريط. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تخزن ليبيزيت في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي التخلص من الأدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تُستعمل. تساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي ليبيزيت على</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إيزيتميب. يحتوي كل قرص على 10 ملجم إيزيتميب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشمل المكونات الأخرى: مونوهيدات اللاكتوز، سليلوز دقيق التبلور، البوفيدون، كروسكارميلوز الصوديوم، سلفات لوريل الصوديوم، فيومارات ستياريل الصوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص ليبيزيت بيضاء اللون، مستطيلة الشكل، مستوية السطح ذات جوانب مشطوفة، غير محززة من المنتصف ومنقوش عليها الرمزEZ1.</p><p dir="RTL">تحتوي كل علبة على 28 قرصاً (في شرائط منقطة يحتوي كل شريط على 7 أقراص).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مختبرات سينفا، ش.م.</p><p dir="RTL">شارع أولاز شيبي، 10 منطقة بوليغنو الصناعية.</p><p>31620 أوارتي بامبولنا (نافارا) - إسبانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أجريت آخر مراجعة لهذه النشرة في أغسطس 2018. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lipizet 10 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 10 mg of ezetimibe.
Excipients(s) with known effect:
Each tablet contains 55 mg of lactose monohydrate. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
White, oblong, flat beveled, non-scored tablet engraved with the code "EZ1".


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shape id="_x0000_s1026" style='position:absolute;
 margin-left:94.4pt;margin-top:13.6pt;width:1pt;height:1pt;z-index:-251658240;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="20,20" o:allowincell="f" path="m,7hhl19,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="3" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><u>Primary &nbsp;H</u>ypercholesterolaemia</p><p>Ezetimibe co-administered with an HMG-CoA reductase inhibitor (statin) is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia who are not appropriately controlled with a statin alone.</p><p>Ezetimibe monotherapy is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia in whom a statin is considered inappropriate or is not tolerated.</p><p><strong><em>Prevention of Cardiovascular Events</em></strong></p><p>Ezetimibe is indicated to reduce the risk of cardiovascular events (see section 5.1) in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiated concomitantly with a statin.</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1027" style='position:absolute;
 margin-left:82pt;margin-top:13.6pt;width:1pt;height:1pt;z-index:-251657216;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="20,20" o:allowincell="f" path="m,7hhl15,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="3" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><!--[if gte vml 1]><v:shape id="_x0000_s1028"
 style='position:absolute;margin-left:153.8pt;margin-top:13.6pt;width:1pt;
 height:1pt;z-index:-251656192;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:text' coordsize="20,20" o:allowincell="f"
 path="m,7hhl19,7e" filled="f" strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="3" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:shape id="_x0000_s1029"
 style='position:absolute;margin-left:276.85pt;margin-top:13.6pt;width:1pt;
 height:1pt;z-index:-251655168;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:text' coordsize="20,20" o:allowincell="f"
 path="m,7hhl4,7e" filled="f" strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="2" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png" /><u>H</u>omozygous <u>Familial H</u>ypercholesterolaemia <u>(</u>HoFH)</p><p>Ezetimibe co-administered with a statin, is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g., LDL apheresis).</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1030" style='position:absolute;
 margin-left:82pt;margin-top:13.6pt;width:1pt;height:1pt;z-index:-251654144;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="20,20" o:allowincell="f" path="m,7hhl15,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="3" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png" /><!--[if gte vml 1]><v:shape id="_x0000_s1031"
 style='position:absolute;margin-left:258pt;margin-top:13.6pt;width:1pt;
 height:1pt;z-index:-251653120;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:text' coordsize="20,20" o:allowincell="f"
 path="m,7hhl4,7e" filled="f" strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="2" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png" /><u>H</u>omozygous <u>Sitosterolaemia (</u>Phytosterolaemia)</p><p>Ezetimibe is indicated as adjunctive therapy to diet for use in patients with homozygous familial sitosterolaemia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shape id="_x0000_s1026" style='position:absolute;
 margin-left:86.35pt;margin-top:13.6pt;width:1.3pt;height:1pt;z-index:-251652096;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="26,20" o:allowincell="f" path="m,7hhl25,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="4" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><u>P</u>osology</p><p>The patient should be on an appropriate lipid-lowering diet and should continue on this diet during treatment with ezetimibe.</p><p>Route of administration is oral. The recommended dose is one ezetimibe 10 mg tablet daily. Ezetimibe can be administered at any time of the day, with or without food.</p><p>When ezetimibe is added to a statin, either the indicated usual initial dose of that particular statin or the already established higher statin dose should be continued. In this setting, the dosage instructions for that particular statin should be consulted.</p><p><strong><em>Use in Patients with Coronary Heart Disease and ACS Event History</em></strong></p><p>For incremental cardiovascular event reduction in patients with coronary heart disease and ACS event history, ezetimibe 10 mg may be administered with a statin with proven cardiovascular benefit.</p><p><em>Co-administration with bile acid sequestrants</em></p><p>Dosing of ezetimibe should occur either &ge; 2 hours before or &ge; 4 hours after administration of a bile acid sequestrant.</p><p><em>Elderly</em></p><p>No dosage adjustment is required for elderly patients (see section 5.2).</p><p><em>Paediatric population</em></p><p>Initiation of treatment must be performed under review of a specialist.</p><p>Children and adolescents &ge; 6 : The safety and efficacy of ezetimibe in children aged 6 to 17 years has not been established. Current available data are described in sections 4.4, 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p>When ezetimibe is administered with a statin, the dosage instructions for the statin in children should be consulted.</p><p>Children &lt;6 years: The safety and efficacy of ezetimibe in children aged &lt; 6 years has not been established. No data are available.</p><p><em>Hepatic impairment</em></p><p>No dosage adjustment is required in patients with mild hepatic impairment (Child-Pugh score 5 to 6). Treatment with ezetimibe is not recommended in patients with moderate (Child-Pugh score 7 to 9) or severe (Child-Pugh score &gt; 9) liver dysfunction (see sections 4.4 and 5.2).</p><p><em>Renal impairment</em></p><p>No dosage adjustment is required for renally impaired patients (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

When ezetimibe is co-administered with a statin, please refer to the SPC for that particular medicinal product. Therapy with ezetimibe co-administered with a statin is contraindicated during pregnancy and lactation.

Ezetimibe co-administered with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When ezetimibe is co-administered with a statin, please refer to the SPC for that particular medicinal product.</p><p>&nbsp;</p><p><u>Liver Enzymes</u></p><p>In controlled co-administration trials in patients receiving ezetimibe with a statin, consecutive transaminase elevations (&ge; 3 X the upper limit of normal [ULN]) have been observed. When ezetimibe is co-administered with a statin, liver function tests should be performed at initiation of therapy and according to the recommendations of the statin (see section 4.8.).</p><p>In the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), 18,144 patients with coronary heart disease and ACS event history were randomised to receive ezetimibe/simvastatin 10/40 mg daily (n=9067) or simvastatin 40 mg daily (n=9077). During a median follow-up of 6.0 years, the incidence of consecutive elevations of transaminases (&ge;3 X ULN) was 2.5% for ezetimibe/simvastatin and 2.3% for simvastatin (see section 4.8).</p><p>In a controlled clinical study in which over 9000 patients with chronic kidney disease were randomised to receive ezetimibe 10 mg combined with simvastatin 20 mg daily (n=4650) or placebo (n=4620) (median follow-up period of 4.9 years), the incidence of consecutive elevations of transaminases (&gt;3 X ULN) was 0.7% for ezetimibe combined with simvastatin and 0.6% for placebo (see section 4.8).</p><p>&nbsp;</p><p><u>Skeletal Muscle</u></p><p>In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported. Most patients who developed rhabdomyolysis were taking a statin concomitantly with ezetimibe. However, rhabdomyolysis has been reported very rarely with ezetimibe monotherapy and very rarely with the addition of ezetimibe to other agents known to be associated with increased risk of rhabdomyolysis. If myopathy is suspected based on muscle symptoms or is confirmed by a creatine phosphokinase (CPK) level &gt;10 times the ULN, ezetimibe, any statin, and any of these other agents that the patient is taking concomitantly should be immediately discontinued. All patients starting therapy with ezetimibe should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness or weakness (see section 4.8).</p><p>In IMPROVE-IT, 18,144 patients with coronary heart disease and ACS event history were randomised to receive ezetimibe/simvastatin 10/40 mg daily (n=9067) or simvastatin 40 mg daily (n=9077). During a median follow-up of 6.0 years, the incidence of myopathy was 0.2% for ezetimibe/simvastatin and 0.1% for simvastatin, where myopathy was defined as unexplained muscle weakness or pain with a serum CK &ge;10 times ULN or two consecutive observations of CK &ge;5 and &lt;10 times ULN. The incidence of rhabdomyolysis was 0.1% for ezetimibe/simvastatin and 0.2% for simvastatin, where rhabdomyolysis was defined as unexplained muscle weakness or pain with a serum CK &ge;10 times ULN with evidence of renal injury, &ge;5 times ULN and &lt;10 times ULN on two consecutive occasions with evidence of renal injury or CK &ge;10,000 IU/L without evidence of renal injury. (See section 4.8.)</p><p>&nbsp;</p><p>In a clinical trial in which over 9000 patients with chronic kidney disease were randomised to receive ezetimibe 10 mg combined with simvastatin 20 mg daily (n=4650) or placebo (n=4620) (median follow-up 4.9 years), the incidence of myopathy/rhabdomyolysis was 0.2% for ezetimibe combined with simvastatin and 0.1% for placebo (see section 4.8).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, ezetimibe is not recommended (see section 5.2).</p><p><u>Paediatric population</u></p><p>Efficacy and safety of ezetimibe in patients 6 to10 years of age with heterozygous familial or non-familial hypercholesterolaemia have been evaluated in a 12-week placebo-controlled clinical trial. Effects of ezetimibe for treatment periods &gt; 12 weeks have not been studied in this age group (see sections 4.2, 4.8, 5.1 and 5.2).</p><p>Ezetimibe has not been studied in patients younger than 6 years of age (see sections 4.2 and 4.8.).</p><p>Efficacy and safety of ezetimibe co-administered with simvastatin in patients 10 to 17 years of age with heterozygous familial hypercholesterolaemia have been evaluated in a controlled clinical trial in adolescent boys (Tanner stage II or above) and in girls who were at least one year post-menarche.</p><p>In this limited controlled study, there was generally no detectable effect on growth or sexual maturation in the adolescent boys or girls, or any effect on menstrual cycle length in girls. However, the effects of ezetimibe for a treatment period &gt; 33 weeks on growth and sexual maturation have not been studied (see sections 4.2 and 4.8).</p><p>The safety and efficacy of ezetimibe co-administered with doses of simvastatin above 40mg daily have not been studied in paediatric patients 10 to 17 years of age.</p><p>The safety and efficacy of ezetimibe co-administered with simvastatin have not been studied in paediatric patients &lt; 10 years of age (see sections 4.2 and 4.8).</p><p>The long-term efficacy of therapy with ezetimibe in patients below 17 years of age to reduce morbidity and mortality in adulthood has not been studied.</p><p>&nbsp;</p><p><u>Fibrates</u></p><p>The safety and efficacy of ezetimibe administered with fibrates have not been established.</p><p>If cholelithiasis is suspected in a patient receiving ezetimibe and fenofibrate, gallbladder investigations are indicated and this therapy should be discontinued (see sections 4.5 and 4.8).</p><p><u>Ciclosporin</u></p><p>Caution should be exercised when initiating ezetimibe in the setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving ezetimibe and ciclosporin (see section 4.5).</p><p><u>Anticoagulants</u></p><p>If ezetimibe is added to warfarin, another coumarin anticoagulant, or fluindione, the International Normalised Ratio (INR) should be appropriately monitored (see section 4.5).</p><p><u>Excipient</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In preclinical studies, it has been shown that ezetimibe does not induce cytochrome P450 drug metabolising enzymes. No clinically significant pharmacokinetic interactions have been observed between ezetimibe and drugs known to be metabolised by cytochromes P450 1A2, 2D6, 2C8, 2C9, and 3A4, or N-acetyltransferase.</p><p>In clinical interaction studies, ezetimibe had no effect on the pharmacokinetics of dapsone, dextromethorphan, digoxin, oral contraceptives (ethinyl estradiol and levonorgestrel), glipizide, tolbutamide, or midazolam during co-administration. Cimetidine, co-administered with ezetimibe, had no effect on the bioavailability of ezetimibe.</p><p>&nbsp;</p><p><u>Antacids</u></p><p>Concomitant antacid administration decreased the rate of absorption of ezetimibe but had no effect on the bioavailability of ezetimibe. This decreased rate of absorption is not considered clinically significant.</p><p>&nbsp;</p><p><u>Cholestyramine</u></p><p>Concomitant cholestyramine administration decreased the mean area under the curve (AUC) of total ezetimibe (ezetimibe + ezetimibe glucuronide) approximately 55 %. The incremental low-density lipoprotein cholesterol (LDL-C) reduction due to adding ezetimibe to cholestyramine may be lessened by this interaction (see section 4.2).</p><p>&nbsp;</p><p><u>Fibrates</u></p><p>In patients receiving fenofibrate and ezetimibe, physicians should be aware of the possible risk of cholelithiasis and gallbladder disease (see sections 4.4 and 4.8).</p><p>If cholelithiasis is suspected in a patient receiving ezetimibe and fenofibrate, gallbladder investigations are indicated and this therapy should be discontinued (see section 4.8).</p><p>Concomitant fenofibrate or gemfibrozil administration modestly increased total ezetimibe concentrations (approximately 1.5- and 1.7-fold respectively).</p><p>Co-administration of ezetimibe with other fibrates has not been studied.</p><p>Fibrates may increase cholesterol excretion into the bile, leading to cholelithiasis. In animal studies, ezetimibe sometimes increased cholesterol in the gallbladder bile but not in all species (see section 5.3). A lithogenic risk associated with the therapeutic use of ezetimibe cannot be ruled out.</p><p>&nbsp;</p><p><u>Statins</u></p><p>No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin.</p><p>&nbsp;</p><p><u>C</u>iclosporin</p><p>In a study of eight post-renal transplant patients with creatinine clearance of &gt; 50 mL/min on a stable dose of ciclosporin, a single 10-mg dose of ezetimibe resulted in a 3.4-fold (range 2.3- to 7.9-fold) increase in the mean AUC for total ezetimibe compared to a healthy control population, receiving ezetimibe alone, from another study (n=17). In a different study, a renal transplant patient with severe renal impairment who was receiving ciclosporin and multiple other medications demonstrated a 12-fold greater exposure to total ezetimibe compared to concurrent controls receiving ezetimibe alone.</p><p>In a two-period crossover study in twelve healthy subjects, daily administration of 20 mg ezetimibe for 8 days with a single 100-mg dose of ciclosporin on Day 7 resulted in a mean 15 % increase in ciclosporin AUC (range 10 % decrease to 51 % increase) compared to a single 100-mg dose of ciclosporin alone. A controlled study on the effect of co- administered ezetimibe on ciclosporin exposure in renal transplant patients has not been conducted. Caution should be exercised when initiating ezetimibe in the setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving ezetimibe and ciclosporin (see section 4.4).</p><p>&nbsp;</p><p><u>Anticoagulants</u></p><p>Concomitant administration of ezetimibe (10 mg once daily) had no significant effect on bioavailability of warfarin and prothrombin time in a study of twelve healthy adult males. However, there have been post-marketing reports of increased International Normalised Ratio (INR) in patients who had ezetimibe added to warfarin or fluindione. If ezetimibe is added to warfarin, another coumarin anticoagulant, or fluindione, INR should be appropriately monitored (see section 4.4).</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shape id="_x0000_s1026" style='position:absolute;
 margin-left:92.8pt;margin-top:13.6pt;width:1.3pt;height:1pt;z-index:-251651072;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="26,20" o:allowincell="f" path="m,7hhl25,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="3" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><u>Pregnancy</u></p><p>Ezetimibe should be given to pregnant women only if clearly necessary. No clinical data are available on the use of ezetimibe during pregnancy. Animal studies on the use of ezetimibe in monotherapy have shown no evidence of direct or indirect harmful effects on pregnancy, embryofoetal development, birth or postnatal development (see section 5.3).</p><p><u>Lactation</u></p><p>Ezetimibe should not be used during lactation. Studies on rats have shown that ezetimibe is secreted into breast milk. It is not known if ezetimibe is secreted into human breast milk.</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1027" style='position:absolute;
 margin-left:77.65pt;margin-top:13.6pt;width:1.3pt;height:1pt;z-index:-251650048;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="26,20" o:allowincell="f" path="m,7hhl25,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="3" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><u>Fertility</u></p><p>No clinical trial data are available on the effects of ezetimibe on human fertility. Ezetimibe had no effect on the fertility of male or female rats (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, when driving vehicles or operating machines, it should be taken into account that dizziness has been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><v:shape id="_x0000_s1026"
 style='position:absolute;margin-left:402.15pt;margin-top:9.65pt;width:1pt;
 height:1pt;z-index:-251649024;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:text' coordsize="20,20" o:allowincell="f"
 path="m,7hhl4,7e" filled="f" strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="2" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><u>Tabulated</u><u> </u><u>list of adverse reactions (clinical studies and post-marketing experience)</u></p><p>In clinical studies of up to 112 weeks duration, ezetimibe 10 mg daily was administered alone in 2396 patients, with a statin in 11,308 patients or with fenofibrate in 185 patients. Adverse reactions were usually mild and transient. The overall incidence of side effects was similar between ezetimibe and placebo. Similarly, the discontinuation rate due to adverse experiences was comparable between ezetimibe and placebo.</p><p>Ezetimibe administered alone or co-administered with a statin:</p><p>The following adverse reactions were observed in patients treated with ezetimibe (N=2396) and at a greater incidence than placebo (N=1159) or in patients treated with ezetimibe coadministered with a statin (N=11308) and at a greater incidence than statin administered alone (N=9361). Post-marketing Adverse reactions were derived from reports containing ezetimibe either administered alone or with a statin.</p><p>Frequencies are defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) and not known (cannot be estimated from the available data)</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Ezetimibe monotherapy</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>ALT and/or AST increased; blood CPK increased; gamma-glutamyltransferase increased; liver function test abnormal</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, Thoracic and Mediastinal Disorders</p></td><td style="vertical-align:top"><p>cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>abdominal pain; diarrhoea; flatulence</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>dyspepsia; gastrooesophageal reflux disease; nausea</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal And Connective Tissue Disorders</p></td><td style="vertical-align:top"><p>arthralgia; muscle spasms; neck pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td style="vertical-align:top"><p>decreased appetite</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vascular Disorders</p></td><td style="vertical-align:top"><p>hot flush; hypertension</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General Disorders And Administration Site Condition</p></td><td style="vertical-align:top"><p>fatigue</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>chest pain, pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Additional adverse reactions with ezetimibe co-administered with a statin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>ALT and/or AST increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>paraesthesia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>dry mouth; gastritis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Skin And Subcutaneous Tissue Disorders</p></td><td style="vertical-align:top"><p>pruritus; rash; urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal And Connective Tissue Disorders</p></td><td style="vertical-align:top"><p>myalgia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>back pain; muscular weakness; pain in extremity</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>General Disorders And Administration Site Condition</p></td><td style="vertical-align:top"><p>asthenia; oedema peripheral</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Post-marketing Experience (with or without a statin)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>thrombocytopaenia</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders:</p></td><td style="vertical-align:top"><p>dizziness; paraesthesia</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>dyspnoea</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>pancreatitis; constipation</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>erythema multiforme</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorder</p></td><td style="vertical-align:top"><p>myalgia; &nbsp;myopathy/rhabdomyolysis (see section 4.4)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>asthenia</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>hypersensitivity, including rash, urticaria, anaphylaxis and angio- oedema</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>hepatitis; cholelithiasis; cholecystitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>depression</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Ezetimibe co-administered with fenofibrate</u></p><p>Gastrointestinal disorders: abdominal pain (common)</p><p>In a multicentre, double-blind, placebo-controlled, clinical study in patients with mixed hyperlipidaemia, 625 patients were treated for up to 12 weeks and 576 patients for up to 1 year. In this study, 172 patients treated with ezetimibe and fenofibrate completed 12 weeks of therapy, and 230 patients treated with ezetimibe and fenofibrate (including 109 who received ezetimibe alone for the first 12 weeks) completed 1 year of therapy. This study was not designed to compare treatment groups for infrequent events. Incidence rates (95 % CI) for clinically important elevations (&gt; 3 X ULN, consecutive) in serum transaminases were 4.5 % (1.9, 8.8) and 2.7 % (1.2, 5.4) for fenofibrate monotherapy and ezetimibe co-administered with fenofibrate, respectively, adjusted for treatment exposure. Corresponding incidence rates for cholecystectomy were 0.6 % (0.0, 3.1) and 1.7 % (0.6, 4.0) for fenofibrate monotherapy and ezetimibe co-administered with fenofibrate, respectively (see sections 4.4 and 4.5).</p><p><u>Paediatric (6 to 17 years of age) Patients</u></p><p>In a study involving paediatric (6 to 10 years of age) patients with heterozygous familial or non-familial hypercholesterolaemia (n=138), elevations of ALT and/or AST (&ge; 3X ULN, consecutive) were observed in 1.1% (1 patient) of the ezetimibe patients compared to 0% in the placebo group. There were no elevations of CPK (&ge; 10X ULN). No cases of myopathy were reported.</p><p>In a separate study involving adolescent (10 to 17 years of age) patients with heterozygous familial hypercholesterolaemia (n=248), elevations of ALT and/or AST (&ge; 3X ULN, consecutive) were observed in 3% (4 patients) of the ezetimibe/simvastatin patients compared to 2% (2 patients) in the simvastatin monotherapy group; these figures were respectively 2% (2 patients) and 0% for elevation of CPK (&ge; 10X ULN). No cases of myopathy were reported.</p><p>These trials were not suited for comparison of rare adverse drug reactions.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1027" style='position:absolute;
 margin-left:310.35pt;margin-top:13.6pt;width:1.3pt;height:1pt;z-index:-251648000;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="26,20" o:allowincell="f" path="m,7hhl25,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="3" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /><u>Patients with Coronary Heart Disease and ACS Event History</u></p><p>In the IMPROVE-IT study (see section 5.1), involving 18,144 patients treated with either ezetimibe/simvastatin 10/40 mg (n=9067; of whom 6% were uptitrated to ezetimibe/simvastatin 10/80 mg) or simvastatin 40 mg (n=9077; of whom 27% were uptitrated to simvastatin 80 mg), the safety profiles were similar during a median follow-up period of 6.0 years<em>.</em></p><p>Discontinuation rates due to adverse experiences were 10.6% for patients treated with ezetimibe/simvastatin and 10.1% for patients treated with simvastatin. The incidence of myopathy was 0.2% for ezetimibe/simvastatin and 0.1% for simvastatin, where myopathy was defined as unexplained muscle weakness or pain with a serum CK &ge;10 times ULN or two consecutive observations of CK &ge;5 and &lt;10 times ULN. The incidence of rhabdomyolysis was 0.1% for ezetimibe/simvastatin and 0.2% for simvastatin, where rhabdomyolysis was defined as unexplained muscle weakness or pain with a serum CK &ge;10 times ULN with evidence of renal injury, &ge;5 times ULN and &lt;10 times ULN on two consecutive occasions with evidence of renal injury or CK &ge;10,000 IU/L without evidence of renal injury. The incidence of consecutive elevations of transaminases (&ge;3 X ULN) was 2.5% for ezetimibe/simvastatin and 2.3% for simvastatin (see section 4.4.). Gallbladder-related adverse effects were reported in 3.1% vs 3.5% of patients allocated to ezetimibe/simvastatin and simvastatin, respectively. The incidence of cholecystectomy hospitalisations was 1.5% in both treatment groups. Cancer (defined as any new malignancy) was diagnosed during the trial in 9.4% vs 9.5%, respectively.</p><p>&nbsp;</p><p><u>Patients with Chronic Kidney Disease</u></p><p>In the Study of Heart and Renal Protection (SHARP) (see section 5.1), involving over 9000 patients treated with a fixed dose combination of ezetimibe 10 mg with simvastatin 20 mg daily (n=4650) or placebo (n=4620), the safety profiles were comparable during a median follow-up period of 4.9 years. In this trial, only serious adverse events and discontinuations due to any adverse events were recorded. Discontinuation rates due to adverse events were comparable (10.4% in patients treated with ezetimibe combined with simvastatin, 9.8% in patients treated with placebo). The incidence of myopathy/rhabdomyolysis was 0.2% in patients treated with ezetimibe combined with simvastatin and 0.1% in patients treated with placebo. Consecutive elevations of transaminases (&gt; 3X ULN) occurred in 0.7% of patients treated with ezetimibe combined with simvastatin compared with 0.6% of patients treated with placebo (see section 4.4.). In this trial, there were no statistically significant increases in the incidence of pre-specified adverse events, including cancer (9.4% for ezetimibe combined with simvastatin, 9.5% for placebo), hepatitis, cholecystectomy or complications of gallstones or pancreatitis.</p><p>&nbsp;</p><p><u>Laboratory &nbsp;values:</u></p><p>In controlled clinical monotherapy trials, the incidence of clinically important elevations in serum transaminases (ALT and/or AST &ge; 3 X ULN, consecutive) was similar between ezetimibe (0.5 %) and placebo (0.3 %). In co-administration trials, the incidence was 1.3 % for patients treated with ezetimibe co-administered with a statin and 0.4 % for patients treated with a statin alone. These elevations were generally asymptomatic, not associated with cholestasis, and returned to baseline after discontinuation of therapy or with continued treatment (see section 4.4.).</p><p>In clinical trials, CPK &gt;10 X ULN was reported for 4 of 1674 (0.2 %) patients administered ezetimibe alone vs 1 of 786 (0.1 %) patients administered placebo, and for 1 of 917 (0.1 %) patients co-administered ezetimibe and a statin vs 4 of 929 (0.4 %) patients administered a statin alone. There was no excess of myopathy or rhabdomyolysis associated with ezetimibe compared with the relevant control arm (placebo or statin alone) (see section 4.4).</p><p>&nbsp;</p><p><u>Reporting</u><u> </u><u>of</u><u> </u><u>suspected</u><u> </u><u>adverse</u><u> reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>To report any side effect(s):</p><p>&ndash; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, or 40 mg/day to 18 patients with primary hypercholesterolaemia for up to 56 days, was generally well tolerated. In animals, no toxicity was observed after single oral doses of 5000 mg/kg of ezetimibe in rats and mice and 3000 mg/kg in dogs.</p><p>A few cases of overdosage with ezetimibe have been reported; most have not been associated with adverse experiences. Reported adverse experiences have not been serious. In the event of an overdose, symptomatic and supportive measures should be employed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other lipid modifying agents, ATC code: C10A X09</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Ezetimibe is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol and related plant sterols. Ezetimibe is orally active and has a mechanism of action that differs from other classes of cholesterol- reducing compounds (e.g., statins, bile acid sequestrants [resins], fibric acid derivatives, and plant stanols). The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol and phytosterols.</p><p>Ezetimibe localises at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver; statins reduce cholesterol synthesis in the liver and together these distinct mechanisms provide complementary cholesterol reduction. In a 2-week clinical study in 18 hypercholesterolaemic patients, ezetimibe inhibited intestinal cholesterol absorption by 54 %, compared with placebo.</p><p><u>Pharmacodynamic effects</u></p><p>A series of preclinical studies was performed to determine the selectivity of ezetimibe for inhibiting cholesterol absorption. ezetimibe inhibited the absorption of [14C]-cholesterol with no effect on the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl estradiol, or fat soluble vitamins A and D.</p><p>Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C.</p><p>Administration of ezetimibe with a statin is effective in reducing the risk of cardiovascular events in patients with coronary heart disease and ACS event history.</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1026" style='position:absolute;
 margin-left:160.65pt;margin-top:13.6pt;width:1.3pt;height:1pt;z-index:-251646976;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="26,20" o:allowincell="f" path="m,7hhl25,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="4" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>In controlled clinical studies, ezetimibe either as monotherapy or co-administered with a statin significantly reduced total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG) and increased high-density lipoprotein cholesterol (HDL-C) in patients with hypercholesterolaemia.</p><p>&nbsp;</p><p><em>Primary Hypercholesterolaemia</em></p><p>In a double-blind, placebo-controlled, 8-week study, 769 patients with hypercholesterolaemia already receiving statin monotherapy and not at National Cholesterol Education Program (NCEP) LDL-C goal (2.6 to 4.1 mmol/l [100 to 160 mg/dl], depending on baseline characteristics) were randomised to receive either ezetimibe 10 mg or placebo in addition to their on-going statin therapy.</p><p>Among statin-treated patients not at LDL-C goal at baseline (~82 %), significantly more patients randomised to ezetimibe achieved their LDL-C goal at study endpoint compared to patients randomised to placebo, 72 % and 19 %, respectively. The corresponding LDL-C reductions were significantly different (25 % and 4 % for ezetimibe versus placebo, respectively). In addition, Ezetimibe, added to on-going statin therapy, significantly decreased total-C, Apo B, TG and increased HDL-C, compared with placebo. Ezetimibe or placebo added to statin therapy reduced median C-reactive protein by 10 % or 0 % from baseline, respectively.</p><p>In two, double-blind, randomised placebo-controlled, 12-week studies in 1719 patients with primary hypercholesterolaemia, Ezetimibe 10 mg significantly lowered total-C (13 %), LDL-C (19 %), Apo B (14 %), and TG (8 %) and increased HDL-C (3 %) compared to placebo. In addition, ezetimibe had no effect on the plasma concentrations of fat- soluble vitamins A, D, and E, no effect on prothrombin time, and, like other lipid lowering agents, did not impair adrenocortical steroid hormone production.</p><p>In a multicenter, double-blind, controlled clinical study (ENHANCE), 720 patients with heterozygous familial hypercholesterolaemia were randomised to receive ezetimibe 10 mg in combination with simvastatin 80 mg (n=357) or simvastatin 80 mg (n=363) for 2 years. The primary objective of the study was to investigate the effect of the ezetimibe/simvastatin combination therapy on carotid artery intima-media thickness (IMT) compared to simvastatin monotherapy. The impact of this surrogate marker on cardiovascular morbidity and mortality is still not demonstrated.</p><p>The primary endpoint, the change in the mean IMT of all six carotid segments, did not differ significantly (p= 0.29) between the two treatment groups as measured by B-mode ultrasound. With ezetimibe 10 mg in combination with simvastatin 80 mg or simvastatin 80 mg alone, intima-medial thickening increased by 0.0111 mm and 0.0058 mm, respectively, over the study&#39;s 2 year duration (baseline mean carotid IMT 0.68 mm and 0.69 mm respectively.</p><p>Ezetimibe 10 mg in combination with simvastatin 80 mg lowered LDL-C, total-C, Apo B, and TG significantly more than simvastatin 80 mg. The percent increase in HDL-C was similar for the two treatment groups. The adverse reactions reported for ezetimibe 10 mg in combination with simvastatin 80 mg were consistent with its known safety profile.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>In a multicentre, double-blind, controlled study, 138 patients (59 boys and 79 girls), 6 to 10 years of age (mean age 8.3 years) with heterozygous familial or non-familial hypercholesterolaemia (HeFH) with baseline LDL-C levels between 3.74 and 9.92 mmol/l were randomised to either ezetimibe 10 mg or placebo for 12 weeks.</p><p>At week 12, ezetimibe significantly reduced total-C (-21% vs. 0%), LDL-C (-28% vs. -1%), Apo-B (-22% vs. -1%), and non- HDL-C (-26% vs. 0%) compared to placebo. Results for the two treatment groups were similar for TG and HDL-C (-6% vs. +8%, and +2% vs. +1%, respectively).</p><p>In a multicentre, double-blind, controlled study, 142 boys (Tanner stage II and above) and 106 postmenarchal girls, 10 to 17 years of age (mean age 14.2 years) with heterozygous familial hypercholesterolaemia (HeFH) with baseline LDL-C levels between 4.1 and 10.4 mmol/l were randomised to either ezetimibe 10 mg co-administered with simvastatin (10, 20 or 40 mg) or simvastatin (10, 20 or 40 mg) alone for 6 weeks, co-administered ezetimibe and 40 mg simvastatin or 40 mg simvastatin alone for the next 27 weeks, and open-label co-administered ezetimibe and simvastatin (10 mg, 20 mg, or 40 mg) for 20 weeks thereafter.</p><p>At Week 6, ezetimibe co-administered with simvastatin (all doses) significantly reduced total-C (38 % vs 26 %), LDL-C (49</p><p>% vs 34 %), Apo B (39 % vs 27 %), and non-HDL-C (47 % vs 33 %) compared to simvastatin (all doses) alone. Results for the two treatment groups were similar for TG and HDL-C (-17 % vs -12 % and +7 % vs +6 %, respectively). At Week 33, results were consistent with those at Week 6 and significantly more patients receiving ezetimibe and 40 mg simvastatin (62 %) attained the NCEP AAP ideal goal (&lt; 2.8 mmol/L [110 mg/dL]) for LDL-C compared to those receiving 40 mg simvastatin (25 %). At Week 53, the end of the open label extension, the effects on lipid parameters were maintained.</p><p>The safety and efficacy of ezetimibe co-administered with doses of simvastatin above 40 mg daily have not been studied in paediatric patients 10 to 17 years of age. The safety and efficacy of ezetimibe co-administered with simvastatin have not been studied in paediatric patients &lt; 10 years of age.</p><p>The long-term efficacy of therapy with ezetimibe in patients below 17 years of age to reduce morbidity and mortality in adulthood has not been studied.</p><p><em>Prevention of Cardiovascular Events</em></p><p>The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) was a multicenter, randomised, double-blind, active-control study of 18,144 patients enrolled within 10 days of hospitalisation for acute coronary syndrome (ACS; either acute myocardial infarction [MI] or unstable angina [UA]). Patients had an LDL-C &le;125 mg/dL (&le;3.2 mmol/L) at the time of presentation with ACS if they had not been taking lipid-lowering therapy, or &le;100 mg/dL (&le;2.6 mmol/L) if they had been receiving lipid-lowering therapy. All patients were randomised in a 1:1 ratio to receive either ezetimibe/simvastatin 10/40 mg (n=9067) or simvastatin 40 mg (n=9077) and followed for a median of 6.0 years.</p><p>Patients had a mean age of 63.6 years; 76% were male, 84% were Caucasian, and 27% were diabetic. The average LDL-C value at the time of study qualifying event was 80 mg/dL (2.1 mmol/L) for those on lipid-lowering therapy (n=6390) and 101 mg/dL (2.6 mmol/L) for those not on previous lipid-lowering therapy (n=11594). Prior to the hospitalisation for the qualifying ACS event, 34% of the patients were on statin therapy. At one year, the average LDL-C for patients continuing on therapy was 53.2 mg/dL (1.4 mmol/L) for the ezetimibe/simvastatin group and 69.9 mg/dL (1.8 mmol/L) for the simvastatin monotherapy group. Lipid values were generally obtained for patients who remained on study therapy.</p><p>The primary endpoint was a composite consisting of cardiovascular death, major coronary events (MCE; defined as non- fatal myocardial infarction, documented unstable angina that required hospitalisation, or any coronary revascularisation procedure occurring at least 30 days after randomised treatment assignment) and non-fatal stroke. The study demonstrated that treatment with ezetimibe when added to simvastatin provided incremental benefit in reducing the primary composite endpoint of cardiovascular death, MCE, and non-fatal stroke compared with simvastatin alone (relative risk reduction of 6.4%, p=0.016). The primary endpoint occurred in 2572 of 9067 patients (7-year Kaplan-Meier [KM] rate 32.72%) in the ezetimibe/simvastatin group and 2742 of 9077 patients (7-year KM rate 34.67%) in the simvastatin alone group. (See Figure 1 and Table 1.) This incremental benefit is expected to be similar with coadministration of other statins shown to be effective in reducing the risk of cardiovascular events. Total mortality was unchanged in this high risk group (see Table 1).</p><p>There was an overall benefit for all strokes; however there was a small non-significant increase in haemorrhagic stroke in the ezetimibe-simvastatin group compared with simvastatin alone (see Table 1). The risk of haemorrhagic stroke for ezetimibe coadministered with higher potency statins in long-term outcome studies has not been evaluated.</p><p>The treatment effect of ezetimibe/simvastatin was generally consistent with the overall results across many subgroups, including sex, age, race, medical history of diabetes mellitus, baseline lipid levels, prior statin therapy, prior stroke, and hypertension.</p><p>Figure 1: Effect of ezetimibe/Simvastatin on the Primary Composite Endpoint of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke</p><p>Table 1</p><p>Major Cardiovascular Events by Treatment Group in All Randomised Patients in IMPROVE-IT</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:596px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Outcome</u></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Ezetimibe/Simvastatin 10/40 mga</strong></p><p><strong>(N=9067)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Simvastatin 40 mgb&nbsp;(N=9077)</strong></p></td><td style="vertical-align:top"><p><strong>Hazard Ratio</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>p-value</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>K-M % c</p></td><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>K-M % c</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Primary Composite Efficacy Endpoint</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>(CV death, Major Coronary Events and non-fatal stroke)</p></td><td style="vertical-align:top"><p>2572</p></td><td style="vertical-align:top"><p>32.72%</p></td><td style="vertical-align:top"><p>2742</p></td><td style="vertical-align:top"><p>34.67%</p></td><td style="vertical-align:top"><p>0.936 (0.887,</p><p>0.988)</p></td><td style="vertical-align:top"><p>0.016</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Secondary Composite Efficacy Endpoints</strong></p></td></tr><tr><td style="vertical-align:top"><p>CHD death, nonfatal MI, urgent coronary revascularisation after 30 days</p></td><td style="vertical-align:top"><p>1322</p></td><td style="vertical-align:top"><p>17.52%</p></td><td style="vertical-align:top"><p>1448</p></td><td style="vertical-align:top"><p>18.88%</p></td><td style="vertical-align:top"><p>0.912 (0.847,</p><p>0.983)</p></td><td style="vertical-align:top"><p>0.016</p></td></tr><tr><td style="vertical-align:top"><p>MCE, non-fatal stroke, death (all causes)</p></td><td style="vertical-align:top"><p>3089</p></td><td style="vertical-align:top"><p>38.65%</p></td><td style="vertical-align:top"><p>3246</p></td><td style="vertical-align:top"><p>40.25%</p></td><td style="vertical-align:top"><p>0.948 (0.903,</p><p>0.996)</p></td><td style="vertical-align:top"><p>0.035</p></td></tr><tr><td style="vertical-align:top"><p>CV death, non- fatal MI, unstable angina requiring hospitalisation, any revascularisation, non-fatal stroke</p></td><td style="vertical-align:top"><p>2716</p></td><td style="vertical-align:top"><p>34.49%</p></td><td style="vertical-align:top"><p>2869</p></td><td style="vertical-align:top"><p>36.20%</p></td><td style="vertical-align:top"><p>0.945 (0.897,</p><p>0.996)</p></td><td style="vertical-align:top"><p>0.035</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Components of Primary Composite Endpoint and Select Efficacy Endpoints </strong>(first occurrences of specified event at any time)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular death</p></td><td style="vertical-align:top"><p>537</p></td><td style="vertical-align:top"><p>6.89%</p></td><td style="vertical-align:top"><p>538</p></td><td style="vertical-align:top"><p>6.84%</p></td><td style="vertical-align:top"><p>1.000 (0.887,</p><p>1.127)</p></td><td style="vertical-align:top"><p>0.997</p></td></tr><tr><td style="vertical-align:top"><p>Major Coronary Event:</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Non-fatal MI</p></td><td style="vertical-align:top"><p>945</p></td><td style="vertical-align:top"><p>12.77%</p></td><td style="vertical-align:top"><p>1083</p></td><td style="vertical-align:top"><p>14.41%</p></td><td style="vertical-align:top"><p>0.871 (0.798,</p><p>0.950)</p></td><td style="vertical-align:top"><p>0.002</p></td></tr><tr><td style="vertical-align:top"><p>Unstable angina requiring hospitalisation</p></td><td style="vertical-align:top"><p>156</p></td><td style="vertical-align:top"><p>2.06%</p></td><td style="vertical-align:top"><p>148</p></td><td style="vertical-align:top"><p>1.92%</p></td><td style="vertical-align:top"><p>1.059 (0.846,</p><p>1.326)</p></td><td style="vertical-align:top"><p>0.618</p></td></tr><tr><td style="vertical-align:top"><p>Coronary revascularisation after 30 days</p></td><td style="vertical-align:top"><p>1690</p></td><td style="vertical-align:top"><p>21.84%</p></td><td style="vertical-align:top"><p>1793</p></td><td style="vertical-align:top"><p>23.36%</p></td><td style="vertical-align:top"><p>0.947 (0.886,</p><p>1.012)</p></td><td style="vertical-align:top"><p>0.107</p></td></tr><tr><td style="vertical-align:top"><p>Non-fatal stroke</p></td><td style="vertical-align:top"><p>245</p></td><td style="vertical-align:top"><p>3.49%</p></td><td style="vertical-align:top"><p>305</p></td><td style="vertical-align:top"><p>4.24%</p></td><td style="vertical-align:top"><p>0.802 (0.678,</p><p>0.949)</p></td><td style="vertical-align:top"><p>0.010</p></td></tr><tr><td style="vertical-align:top"><p>All MI (fatal and non-fatal)</p></td><td style="vertical-align:top"><p>977</p></td><td style="vertical-align:top"><p>13.13%</p></td><td style="vertical-align:top"><p>1118</p></td><td style="vertical-align:top"><p>14.82%</p></td><td style="vertical-align:top"><p>0.872 (0.800,</p><p>0.950)</p></td><td style="vertical-align:top"><p>0.002</p></td></tr><tr><td style="vertical-align:top"><p>All stroke (fatal and non-fatal)</p></td><td style="vertical-align:top"><p>296</p></td><td style="vertical-align:top"><p>4.16%</p></td><td style="vertical-align:top"><p>345</p></td><td style="vertical-align:top"><p>4.77%</p></td><td style="vertical-align:top"><p>0.857 (0.734,</p><p>1.001)</p></td><td style="vertical-align:top"><p>0.052</p></td></tr><tr><td style="vertical-align:top"><p>Non-hemorrhagic stroke d</p></td><td style="vertical-align:top"><p>242</p></td><td style="vertical-align:top"><p>3.48%</p></td><td style="vertical-align:top"><p>305</p></td><td style="vertical-align:top"><p>4.23%</p></td><td style="vertical-align:top"><p>0.793 (0.670,</p><p>0.939)</p></td><td style="vertical-align:top"><p>0.007</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhagic stroke</p></td><td style="vertical-align:top"><p>59</p></td><td style="vertical-align:top"><p>0.77%</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>0.59%</p></td><td style="vertical-align:top"><p>1.377 (0.930,</p><p>2.040)</p></td><td style="vertical-align:top"><p>0.110</p></td></tr><tr><td style="vertical-align:top"><p>Death from any cause</p></td><td style="vertical-align:top"><p>1215</p></td><td style="vertical-align:top"><p>15.36%</p></td><td style="vertical-align:top"><p>1231</p></td><td style="vertical-align:top"><p>15.28%</p></td><td style="vertical-align:top"><p>0.989 (0.914,</p><p>1.070)</p></td><td style="vertical-align:top"><p>0.782</p></td></tr></tbody></table><p>a&nbsp;6% were uptitrated to ezetimibe/simvastatin 10/80 mg.</p><p>b 27% were uptitrated to simvastatin 80 mg.</p><p>c Kaplan-Meier estimate at 7 years.</p><p>d includes ischemic stroke or stroke of undetermined type.</p><p>&nbsp;</p><p><em>Prevention of Major Vascular Events in Chronic Kidney Disease (CKD)</em></p><p>The Study of Heart and Renal Protection (SHARP) was a multi-national, randomised, placebo-controlled, double-blind study conducted in 9438 patients with chronic kidney disease, a third of whom were on dialysis at baseline. A total of 4650 patients were allocated to a fixed dose combination of ezetimibe 10 mg with simvastatin 20 mg and 4620 to placebo, and followed for a median of 4.9 years. Patients had a mean age of 62 and 63 % were male, 72 % Caucasian, 23 % diabetic and, for those not on dialysis, the mean estimated glomerular filtration rate (eGFR) was 26.5 ml/min/1.73 m2. There were no lipid entry criteria. Mean LDL-C at baseline was 108 mg/dL. After one year, including patients no longer taking study medication, LDL-C was reduced 26 % relative to placebo by simvastatin 20 mg alone and 38 % by ezetimibe 10 mg combined with simvastatin 20 mg.</p><p>The SHARP protocol-specified primary comparison was an intention-to-treat analysis of &quot;major vascular events&quot; (MVE; defined as nonfatal MI or cardiac death, stroke, or any revascularisation procedure) in only those patients initially randomised to the ezetimibe combined with simvastatin (n=4193) or placebo (n=4191) groups. Secondary analyses included the same composite analyzed for the full cohort randomised (at study baseline or at year 1) to ezetimibe combined with simvastatin (n=4650) or placebo (n=4620) as well as the components of this composite.</p><p>The primary endpoint analysis showed that ezetimibe combined with simvastatin significantly reduced the risk of major vascular events (749 patients with events in the placebo group vs. 639 in the ezetimibe combined with simvastatin group) with a relative risk reduction of 16 % (p=0.001).</p><p>Nevertheless, this study design did not allow for a separate contribution of the monocomponent ezetimibe to efficacy to significantly reduce the risk of major vascular events in patients with CKD.</p><p>The individual components of MVE in all randomised patients are presented in Table 2. Ezetimibe combined with simvastatin significantly reduced the risk of stroke and any revascularisation, with non-significant numerical differences favouring ezetimibe combined with simvastatin for nonfatal MI and cardiac death.</p><p>Table 2</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1027" style='position:absolute;
 margin-left:411.55pt;margin-top:67.45pt;width:1pt;height:1pt;z-index:-251645952;
 mso-position-horizontal-relative:page;mso-position-vertical-relative:text'
 coordsize="20,20" o:allowincell="f" path="m,7hhl9,7e" filled="f"
 strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="2" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png" /><!--[if gte vml 1]><v:shape id="_x0000_s1028"
 style='position:absolute;margin-left:449.65pt;margin-top:67.45pt;width:1pt;
 height:1pt;z-index:-251644928;mso-position-horizontal-relative:page;
 mso-position-vertical-relative:text' coordsize="20,20" o:allowincell="f"
 path="m,7hhl4,7e" filled="f" strokeweight=".29886mm">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="2" height="2" src="file:///C:/Users/Moustafa/AppData/Local/Temp/msohtmlclip1/01/clip_image004.png" />Major Vascular Events by Treatment Group in all randomised patients in SHARPa</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><u>Outcome</u></p></td><td style="vertical-align:top"><p>Ezetimibe 10 mg combined with simvastatin 20 mg</p><p>(N=4650)</p></td><td style="vertical-align:top"><p><u>Placebo</u> (N=4620)</p></td><td style="vertical-align:top"><p><u>Risk Ratio</u> <u>(</u>95% <u>C</u>I)</p></td><td style="vertical-align:top"><p><u>P-value</u></p></td></tr><tr><td style="vertical-align:top"><p>Major Vascular Events</p></td><td style="vertical-align:top"><p>701 (15.1%)</p></td><td style="vertical-align:top"><p>814 (17.6%)</p></td><td style="vertical-align:top"><p>0.85 (0.77-0.94)</p></td><td style="vertical-align:top"><p>0.001</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal MI</p></td><td style="vertical-align:top"><p>134 (2.9%)</p></td><td style="vertical-align:top"><p>159 (3.4%)</p></td><td style="vertical-align:top"><p>0.84 (0.66-1.05)</p></td><td style="vertical-align:top"><p>0.12</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac Death</p></td><td style="vertical-align:top"><p>253 (5.4%)</p></td><td style="vertical-align:top"><p>272 (5.9%)</p></td><td style="vertical-align:top"><p>0.93 (0.78-1.10)</p></td><td style="vertical-align:top"><p>0.38</p></td></tr><tr><td style="vertical-align:top"><p>Any Stroke</p></td><td style="vertical-align:top"><p>171 (3.7%)</p></td><td style="vertical-align:top"><p>210 (4.5%)</p></td><td style="vertical-align:top"><p>0.81 (0.66-0.99)</p></td><td style="vertical-align:top"><p>0.038</p></td></tr><tr><td style="vertical-align:top"><p>Non-hemorrhagic Stroke</p></td><td style="vertical-align:top"><p>131 (2.8%)</p></td><td style="vertical-align:top"><p>174 (3.8%)</p></td><td style="vertical-align:top"><p>0.75 (0.60-0.94)</p></td><td style="vertical-align:top"><p>0.011</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhagic Stroke</p></td><td style="vertical-align:top"><p>45 (1.0%)</p></td><td style="vertical-align:top"><p>37 (0.8%)</p></td><td style="vertical-align:top"><p>1.21 (0.78-1.86)</p></td><td style="vertical-align:top"><p>0.40</p></td></tr><tr><td style="vertical-align:top"><p>Any Revascularisation</p></td><td style="vertical-align:top"><p>284 (6.1%)</p></td><td style="vertical-align:top"><p>352 (7.6%)</p></td><td style="vertical-align:top"><p>0.79 (0.68-0.93)</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>Major Atherosclerotic Events (MAE)b</p></td><td style="vertical-align:top"><p>526 (11.3%)</p></td><td style="vertical-align:top"><p>619 (13.4%)</p></td><td style="vertical-align:top"><p>0.83 (0.74-0.94)</p></td><td style="vertical-align:top"><p>0.002</p></td></tr></tbody></table><p>aIntention-to-treat analysis on all SHARP patients randomised to ezetimibe combined with simvstatin or placebo either at baseline or year 1</p><p>b MAE; defined as the composite of nonfatal myocardial infarction, coronary death, non-hemorrhagic stroke, or any revascularisation</p><p>The absolute reduction in LDL cholesterol achieved with ezetimibe combined with simvastatin was lower among patients with a lower baseline LDL-C (&lt;2.5 mmol/l) and patients on dialysis at baseline than the other patients, and the corresponding risk reductions in these two groups were attenuated.</p><p><em>Homozygous Familial Hypercholesterolaemia (HoFH)</em></p><p>A double-blind, randomised, 12-week study enrolled 50 patients with a clinical and/or genotypic diagnosis of HoFH, who were receiving atorvastatin or simvastatin (40 mg) with or without concomitant LDL apheresis. Ezetimibe co-administered with atorvastatin (40 or 80 mg) or simvastatin (40 or 80 mg), significantly reduced LDL-C by 15 % compared with increasing the dose of simvastatin or atorvastatin monotherapy from 40 to 80 mg.</p><p><em>Homozygous Sitosterolaemia (Phytosterolaemia)</em></p><p>In a double-blind, placebo-controlled, 8-week trial, 37 patients with homozygous sitosterolaemia were randomised to receive ezetimibe 10 mg (n=30) or placebo (n=7). Some patients were receiving other treatments (e.g., statins, resins). Ezetimibe significantly lowered the two major plant sterols, sitosterol and campesterol, by 21 % and 24 % from baseline, respectively. The effects of decreasing sitosterol on morbidity and mortality in this population are not known.</p><p><em>Aortic Stenosis</em></p><p>The Simvastatin and ezetimibe for the Treatment of Aortic Stenosis (SEAS) study was a multi-center, double-blind, placebo-controlled study with a median duration of 4.4 years conducted in 1873 patients with asymptomatic aortic stenosis (AS), documented by Doppler-measured aortic peak flow velocity within the range of 2.5 to 4.0 m/s. Only patients who were considered not to require statin treatment for purposes of reducing atherosclerotic cardiovascular disease risk were enrolled. Patients were randomised 1:1 to receive placebo or co-administered ezetimibe 10 mg and simvastatin 40 mg daily.</p><p>The primary endpoint was the composite of major cardiovascular events (MCE) consisting of cardiovascular death, aortic valve replacement (AVR) surgery, congestive heart failure (CHF) as a result of progression of AS, nonfatal myocardial infarction, coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), hospitalisation for unstable angina, and nonhaemorrhagic stroke. The key secondary endpoints were composites of subsets of the primary endpoint event categories.</p><p>Compared to placebo, ezetimibe/simvastatin 10/40 mg did not significantly reduce the risk of MCE. The primary outcome occurred in 333 patients (35.3%) in the ezetimibe / simvastatin group and in 355 patients (38.2%) in the placebo group (hazard ratio in the ezetimibe / simvastatin group, 0.96; 95% confidence interval, 0.83 to 1.12; p = 0.59). Aortic valve replacement was performed in 267 patients (28.3%) in the ezetimibe / simvastatin group and in 278 patients (29.9%) in the placebo group (hazard ratio, 1.00; 95% CI, 0.84 to 1.18; p = 0.97). Fewer patients had ischemic cardiovascular events in the ezetimibe / simvastatin group (n=148) than in the placebo group (n=187) (hazard ratio, 0.78; 95% CI, 0.63 to 0.97; p = 0.02), mainly because of the smaller number of patients who underwent coronary artery bypass grafting.</p><p>Cancer occurred more frequently in the ezetimibe / simvastatin group (105 versus 70, p = 0.01). The clinical relevance of this observation is uncertain as in the bigger SHARP trial the total number of patients with any incident cancer (438 in</p><p>the ezetimibe/ simvastatin versus 439 placebo group) did not differ. In addition, in the IMPROVE-IT trial the total number of patients with any new malignancy (853 in the ezetimibe/simvastatin group versus 863 in the simvastatin group) did not differ significantly and therefore the finding of SEAS trial could not be confirmed by SHARP or IMPROVE-IT.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After oral administration, ezetimibe is rapidly absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). Mean maximum plasma concentrations (Cmax) occur within 1 to 2 hours for ezetimibe-glucuronide and 4 to 12 hours for ezetimibe. The absolute bioavailability of ezetimibe cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection.</p><p>Concomitant food administration (high fat or non-fat meals) had no effect on the oral bioavailability of ezetimibe when administered as ezetimibe 10-mg tablets. Ezetimibe can be administered with or without food.</p><p><u>Distribution</u></p><p>Ezetimibe and ezetimibe-glucuronide are bound 99.7 % and 88 to 92 % to human plasma proteins, respectively.</p><p><u>Biotransformation</u></p><p>Ezetimibe is metabolised primarily in the small intestine and liver via glucuronide conjugation (a phase II reaction) with subsequent biliary excretion. Minimal oxidative metabolism (a phase I reaction) has been observed in all species evaluated. Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds detected in plasma, constituting approximately 10 to 20 % and 80 to 90 % of the total drug in plasma, respectively. Both ezetimibe and ezetimibe- glucuronide are slowly eliminated from plasma with evidence of significant enterohepatic recycling. The half-life for ezetimibe and ezetimibe-glucuronide is approximately 22 hours.</p><p><u>Elimination</u></p><p>Following oral administration of 14C-ezetimibe (20 mg) to human subjects, total ezetimibe accounted for approximately 93 % of the total radioactivity in plasma. Approximately 78 % and 11 % of the administered radioactivity were recovered in the faeces and urine, respectively, over a 10-day collection period. After 48 hours, there were no detectable levels of radioactivity in the plasma.</p><p><u>Special Populations</u></p><p><em>Paediatric population</em></p><p>The pharmacokinetics of ezetimibe are similar between children &ge;6 years and adults. Pharmacokinetic data in the paediatric population &lt; 6 years of age are not available. Clinical experience in paediatric and adolescent patients includes patients with HoFH, HeFH, or sitosterolaemia.</p><p><em>Elderly</em></p><p>Plasma concentrations for total ezetimibe are about 2-fold higher in the elderly (&ge; 65 years) than in the young (18 to 45 years). LDL-C reduction and safety profile are comparable between elderly and young subjects treated with ezetimibe.</p><p>Therefore, no dosage adjustment is necessary in the elderly.</p><p><em>Hepatic impairment</em></p><p>After a single 10-mg dose of ezetimibe, the mean AUC for total ezetimibe was increased approximately 1.7-fold in patients with mild hepatic impairment (Child-Pugh score 5 or 6), compared to healthy subjects. In a 14-day, multiple-dose study (10 mg daily) in patients with moderate hepatic impairment (Child-Pugh score 7 to 9), the mean AUC for total ezetimibe was increased approximately 4-fold on Day 1 and Day 14 compared to healthy subjects. No dosage adjustment is necessary for patients with mild hepatic impairment. Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe (Child-Pugh score &gt; 9) hepatic impairment, ezetimibe is not recommended in these patients (see section 4.4).</p><p><em>Renal impairment</em></p><p>After a single 10-mg dose of ezetimibe in patients with severe renal disease (n=8; mean CrCl &le; 30 ml/min/1.73 m2), the mean AUC for total ezetimibe was increased approximately 1.5-fold, compared to healthy subjects (n=9). This result is not considered clinically significant. No dosage adjustment is necessary for renally impaired patients.</p><p>An additional patient in this study (post-renal transplant and receiving multiple medications, including ciclosporin) had a 12-fold greater exposure to total ezetimibe.</p><p><em>Gender</em></p><p>Plasma concentrations for total ezetimibe are slightly higher (approximately 20 %) in women than in men. LDL-C reduction and safety profile are comparable between men and women treated with ezetimibe. Therefore, no dosage adjustment is necessary on the basis of gender.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies on the chronic toxicity of ezetimibe identified no target organs for toxic effects. In dogs treated for four weeks with ezetimibe (&ge; 0.03 mg/kg/day) the cholesterol concentration in the cystic bile was increased by a factor of 2.5 to 3.5. However, in a one-year study on dogs given doses of up to 300 mg/kg/day no increased incidence of cholelithiasis or other hepatobiliary effects were observed. The significance of these data for humans is not known. A lithogenic risk associated with the therapeutic use of ezetimibe cannot be ruled out.</p><p>In co-administration studies with ezetimibe and statins the toxic effects observed were essentially those typically associated with statins. Some of the toxic effects were more pronounced than observed during treatment with statins alone. This is attributed to pharmacokinetic and pharmacodynamic interactions in co-administration therapy. No such interactions occurred in the clinical studies. Myopathies occurred in rats only after exposure to doses that were several times higher than the human therapeutic dose (approximately 20 times the AUC level for statins and 500 to 2000 times the AUC level for the active metabolites).</p><p>In a series of <em>in vivo </em>and <em>in vitro </em>assays ezetimibe, given alone or co-administered with statins, exhibited no genotoxic potential. Long-term carcinogenicity tests on ezetimibe were negative.</p><p>Ezetimibe had no effect on the fertility of male or female rats, nor was it found to be teratogenic in rats or rabbits, nor did it affect prenatal or postnatal development. Ezetimibe crossed the placental barrier in pregnant rats and rabbits given multiple doses of 1000 mg/kg/day. The co-administration of ezetimibe and statins was not teratogenic in rats. In pregnant rabbits a small number of skeletal deformities (fused thoracic and caudal vertebrae, reduced number of caudal vertebrae) were observed. The co-administration of ezetimibe with lovastatin resulted in embryolethal effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium croscarmellose Lactose monohydrate Microcrystalline cellulose Povidone Sodium lauril sulfate</p><p>Sodium stearyl fumarate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets are packaged in Alu/Alu blister.</p><p>Lipizet is contained in packs of 28 tablets (7&rsquo;s blister x 4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LABORATORIOS CINFA, S.A.
Olaz-Chipi,10. Polígono Industrial Areta, 
31620 Huarte-Pamplona (Navarra) – Spain


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                19 February 2018


            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>